# Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer

> **NCT00955305** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 175 (actual)

## Conditions studied

- Large Cell Lung Carcinoma
- Lung Adenocarcinoma
- Recurrent Non-Small Cell Lung Carcinoma
- Stage IV Non-Small Cell Lung Cancer
- Bronchioloalveolar Lung Carcinoma

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **DRUG:** Carboplatin
- **BIOLOGICAL:** Cixutumumab
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT00955305
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-03
- **Primary completion:** 2016-01
- **Final completion:** 2016-11
- **Target enrollment:** 175 (ACTUAL)
- **Why stopped:** The study was closed to accrual due to the end of the clinical development program with cixutumumab.
- **Last updated:** 2018-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00955305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00955305, "Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00955305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*